        |
|
 MultiCell Outlines Portfolio of Next-Generation Immune Modulation Therapeutics Technology in Updated Investor Fact Sheet MultiCell Technologies, Inc. (OTCBB:MCET), developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today announced the online availability of an updated Investor Fact Sheet highlighting the Company's strategic vision for continued growth by developing and commercializing cutting-edge drugs focused on innovative methods of modulating the human immune system. The Company's innovative drug development technologies target a range of serious autoimmune diseases, including multiple sclerosis and type-1 diabetes. Other potential targets of MultiCell's immune system modulation therapies include viral infections such as influenza and bird flu. Currently, the market for therapies addressing these diseases is estimated at approximately $8 billion worldwide. MultiCell's management is committed to the aggressive expansion of its new drug candidate pipeline through acquisition and internal development of potential therapeutic compounds, according to the Investor Fact Sheet. Recently, MultiCell announced that its intellectual property portfolio now totals 54 issued or pending patents that cover novel drug development platform technologies and new drug candidates. Included in that portfolio is a breakthrough patent that applies the Company's immune-based therapeutics to treat malignant tumors in millions of cancer patients around the world. The Investor Fact Sheet highlights the Company's first-in-class therapeutic development pipeline, which includes drugs for treatment of: chronic fatigue in multiple sclerosis patients, relapsing-remitting MS, type-1 diabetes and influenza. To read or download MultiCell's Investor Fact Sheet and learn more about the Company's development initiatives, please visit: http://www.trilogy-capital.com/tcp/multicell/factsheet.html. About MultiCell Technologies, Inc. MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system. The Company's lead drug candidates include drugs to treat MS-related chronic fatigue, relapsing-remitting multiple sclerosis, type-1 diabetes and infectious disease. The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics. For more information about MultiCell Technologies, please visit http://www.MultiCelltech.com. For investor information about MultiCell, please visit http://www.trilogy-capital.com/tcp/multicell. For current stock price quotes and news, visit http://www.trilogy-capital.com/tcp/multicell/quote.html. To view the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/multicell/factsheet.html. To listen to an archived investor conference call, visit http://www.trilogy-capital.com/tcp/multicell/conference.html. Forward-Looking Statements Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could" and "would." Examples of such forward-looking statements include statements regarding plans to develop new drug candidates, plans to expand intellectual property holdings, the ability of MultiCell to accelerate any of its therapeutic programs, or the ability of MultiCell to commercialize any drug candidates. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statements include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our lead drug candidates as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2005, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events. MultiCell Technologies, Inc. Dr. Stephen Chang MCETInvestor@MultiCelltech.com or Trilogy Capital Partners (Financial Communications) Paul Karon, 800-592-6067 paul@trilogy-capital.com Source: Business Wire (October 11, 2006 - 5:30 AM EST) |